Oneness Biotech Co., Ltd.

Fespixon cream has been approved to be reimbursed by the National Health Insurance

2023-07-14

Statement
No	2	Date of announcement	2023/07/14	Time of announcement	20:18:26
Subject	Fespixon cream has been approved to be reimbursed by the National Health Insurance
To which item it meets	paragraph 53			Date of events	2023/07/14
Date of occurrence of the event:2023/07/14 Company name:ONENESS BIOTECH CO., LTD. Relationship to the Company (please enter ”head office” or ”subsidiaries”):head office Reciprocal shareholding ratios:NA Cause of occurrence:Oneness was notified that Fespixon cream has been included in the NHI reimbursement. The reimbursement price will be NT$9,800 per tube and become effective as of 2023/08/01. Countermeasures:NA Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):NA

NEWS